Furthermore, results showing a reduced tumor occurrence in PTEN+/−, PDK1 hypomorphic mice, compared to PTEN+/− mice, strongly support PDK1 as important therapeutic target in cancer driven by alterations of the PI3K pathway [117]. This evidence concerns the gene PTEN and neoplasm.